Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.98 |
| ▸ | PGR | P06401 | 3/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | AR | P10275 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | IKBKB | O14920 | 1/20 | 0.98 |
| ▸ | CHUK | O15111 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.98 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.98 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL588708 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL588707 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL28158165 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL719920 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL1868581 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11904933 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL4847833 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4847837 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1913948-B1 | Re-epithelializing pharmaceutical compositions containing xanthan gum | SIFI SPA (IT) | 2011-10-12 | — | — | EP | claimed |
| JP-2011500184-A | — | — | 2011-01-06 | — | — | JP | claimed |
| US-20100233226-A1 | DRUG-ELUTING NANOWIRE ARRAY | Université Catholique de Louvain (BE) | 2010-09-16 | — | — | US | claimed |
| EP-2205291-A1 | DRUG-ELUTING NANOWIRE ARRAY | Université Catholique de Louvain (BE) | 2010-07-14 | — | — | EP | claimed |
| WO-2009050168-A1 | DRUG-ELUTING NANOWIRE ARRAY | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2009-04-23 | — | — | WO | claimed |
| US-20080139522-A1 | Dexamethasone disodium phosphate;xanthan gum; sodium (di)hydrogen phosphate buffer; sodium citrate; and water; ophthalmology; vision defects; corneal epithelial cells; wound healing agents | SIFI S.P.A.. (IT) | 2008-06-12 | — | — | US | claimed |
| EP-1913948-A1 | Re-epithelializing pharmaceutical compositions containing xanthan gum | Sifi S.p.A (IT) | 2008-04-23 | — | — | EP | claimed |
| US-20050234011-A1 | Use of composition of xanthan gum mixed with hyaluronic acid speeds up and improves advantageously the formation of newly grown epithelium, especially of corneal tissue | SIFI S.P.A. (IT) | 2005-10-20 | — | — | US | claimed |
| US-11883469-B2 | Method of treating spinal cord injury | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2024-01-30 | — | — | US | disclosed |
| EP-3727485-B1 | PHARMACEUTICAL COMPOSITION | UNIV JOHANNESBURG WITWATERSRAND (ZA) | 2023-07-26 | — | — | EP | disclosed |
| CN-111587127-B | Pharmaceutical composition | 约翰内斯堡威特沃特斯兰德大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-112867453-A | Device and method for skinning bone | 华沙整形外科股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112384162-A | Bone material dispensing system with locking member | 华沙整形外科股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200405821-A1 | PHARMACEUTICAL COMPOSITION | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2020-12-31 | — | — | US | disclosed |
| US-20080139502-A1 | Use of xanthan gum as a re-epithelializing active principle eventually mixed with hyaluronic acid; speeds up and improves the formation of newly grown epithelium, especially of the corneal tissue; well tolerated | SIFI S.P.A. (IT) | 2008-06-12 | — | — | US | disclosed |
| US-20080139522-A1 | Dexamethasone disodium phosphate;xanthan gum; sodium (di)hydrogen phosphate buffer; sodium citrate; and water; ophthalmology; vision defects; corneal epithelial cells; wound healing agents | SIFI S.P.A.. (IT) | 2008-06-12 | — | — | US | disclosed |
| EP-1913948-A1 | Re-epithelializing pharmaceutical compositions containing xanthan gum | Sifi S.p.A (IT) | 2008-04-23 | — | — | EP | disclosed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20050234011-A1 | Use of composition of xanthan gum mixed with hyaluronic acid speeds up and improves advantageously the formation of newly grown epithelium, especially of corneal tissue | SIFI S.P.A. (IT) | 2005-10-20 | — | — | US | disclosed |
| WO-1992008474-A2 | TREATMENT OF LUNG DISEASES | THE NATIONAL HEART & LUNG INSTITUTE (GB) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233226-A1 | DRUG-ELUTING NANOWIRE ARRAY | ERBB3, SLC6A2, EPHA2 | NR3C1 1720/4885HIF1A 3951/4885CYP3A4 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.